株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アトピー性皮膚炎:世界の治験動向

Atopic Dermatitis Global Clinical Trials Review, H1, 2017

発行 GlobalData 商品コード 246389
出版日 ページ情報 英文 413 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.90円で換算しております。
Back to Top
アトピー性皮膚炎:世界の治験動向 Atopic Dermatitis Global Clinical Trials Review, H1, 2017
出版日: 2017年04月30日 ページ情報: 英文 413 Pages
概要

当レポートでは、アトピー性皮膚炎に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 主要国における治験件数; 中東/アフリカ地域
    • 主要国における治験件数; 中南米

G7諸国における治験件数:アトピー性皮膚炎治験件数の皮膚病治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:アトピー性皮膚炎治験件数の皮膚病治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - アトピー性皮膚炎治療薬

有望な薬剤

  • 最新治験ニュース:アトピー性皮膚炎

治験プロファイルの基本情報

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's clinical trial report, "Atopic Dermatitis Global Clinical Trials Review, H1, 2017" provides an overview of Atopic Dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on Atopic Dermatitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Atopic Dermatitis to Dermatology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Atopic Dermatitis to Dermatology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Atopic Dermatitis Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Atopic Dermatitis 30
  • Mar 16, 2017: Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis 30
  • Mar 14, 2017: GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic Dermatitis (Eczema) 30
  • Mar 04, 2017: Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of Dupixent (dupilumab) in Moderate-to-Severe Atopic Dermatitis 30
  • Mar 03, 2017: LEO Pharma announces positive results from phase 2b clinical study for tralokinumab in atopic dermatitis 31
  • Mar 02, 2017: Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab (CIM331)" Global Phase II Study Data Published in The New England Journal of Medicine Online 32
  • Feb 28, 2017: FDA Permits Realm Therapeutics to Proceed to Phase II Clinical Trial with PR022 for Atopic Dermatitis 32
  • Feb 28, 2017: KPI Therapeutics Will Present New, Positive Data on KPI-150 as a Potential New Therapy for Atopic Dermatitis at Upcoming Skin Disease Conference 33
  • Feb 27, 2017: Regeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses 33
  • Feb 22, 2017: MatriSys Bioscience announces publication of highly promising results which could translate into clinically meaningful benefits for eighteen million patients with atopic dermatitis 34
  • Jan 30, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR022 for Atopic Dermatitis 34
  • Clinical Trial Profile Snapshots 35

Appendix 410

  • Abbreviations 410
  • Definitions 410
  • Research Methodology 411
  • Secondary Research 411
  • About GlobalData 412
  • Contact Us 412
  • Source 413

List of Tables

List of Tables

  • Atopic Dermatitis Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Atopic Dermatitis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Atopic Dermatitis Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Atopic Dermatitis Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Atopic Dermatitis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
  • Atopic Dermatitis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Atopic Dermatitis to Dermatology Clinical Trials, G7 Countries (%), 2017* 15
  • Atopic Dermatitis Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Atopic Dermatitis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Atopic Dermatitis to Dermatology Clinical Trials, E7 Countries (%), 2017* 18
  • Atopic Dermatitis Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Atopic Dermatitis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Atopic Dermatitis Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Atopic Dermatitis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Atopic Dermatitis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Atopic Dermatitis Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Atopic Dermatitis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Atopic Dermatitis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29

List of Figures

List of Figures

  • Atopic Dermatitis Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Atopic Dermatitis Therapeutics, Global, Clinical Trials
Back to Top